LifeLabs Acquisition, Valuation, Funding & Investors

Novogene Co Ltd is engaged in providing multi-level scientific research and technical services and solutions for life science basic research, medical and clinical application research, and independent development and innovation of genetic testing medical equipment.

Karius is a Redwood City, California-headquartered life sciences company that develops liquid biopsy tests for infectious diseases using next-generation sequencing. The Karius Test analyzes microbial cell-free DNA from blood plasma to identify bacteria, fungi, viruses, and parasites within 24 hours, aiding clinicians at hospitals like Cleveland Clinic and UCSF. Operating a CLIA-certified and CAP-accredited laboratory since 2014, Karius focuses on immunocompromised patients and sepsis cases to enable precise antibiotic stewardship.

Fulgent Genetics Inc is a technology company that focuses on genetic testing to provide physicians with clinically actionable diagnostic information. The company is engaged in laboratory services business and a therapeutic development business. The laboratory services business which generates key revenue includes, technical laboratory services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a broad range of cancers. The geographical segments are the United States, which generates the vast majority of the revenue; and Foreign.

BGI Genomics Co Ltd is a China-based company principally engaged in the provision of genomic class diagnosis and research services through the application of biotechnology. It offers its services in various research areas, such as agriculture and food science, cancer research, metagenomics, reproductive health, biomarker discovery, and drug discovery. The company mainly provides services for domestic and overseas academic institutions hospitals, medical institutions and others.

Clear Labs is a Woburn-based genomics company delivering next-generation sequencing through Clear Dx for pathogen detection in infectious diseases and Clear Safety for food safety contaminants like Salmonella and E. coli. Its platforms support FDA-compliant surveillance and supply chain testing for food producers and public health agencies.

Myriad Genetics Inc is a molecular diagnostics and precision medicine company committed to advancing health and well-being for all. The company develops and commercializes molecular tests that help patients and providers uncover genetic insights. Its tests assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties, supporting earlier detection, more precise treatment, and lowering healthcare costs. Its tests include BRACAnalysis CDx, EndoPredict, FirstGene, Foresight, GeneSight, MyChoice CDx, MyRisk (cancer treatment), MyRisk (cancer risk), Prequel, Precise Tumor, Prolaris, and SneakPeek. The company operates in the US and Rest of World, with maximum revenue from the US.

Azenta Inc provides biological and chemical sample exploration and management solutions, using precision automation and cryogenics to develop automated ultra-cold storage. It serves customers from research to commercialization with sample management, automated storage, genomic services, consumables, informatics, and repository services. The company operates through two segments: Sample Management Solutions, offering SRS and Core Products such as automated stores, cryogenic systems, sample tubes, consumables, instruments, and thawing devices, which generate majority of its revenue; and Multiomics, which provides genomic analysis services. The company operates in United States, China, United Kingdom, rest of Europe, and others, with majority of its revenue in the United States.

Enveda Biosciences is a Mountain View-based biotechnology firm using AI to map chemical structures from natural sources for drug discovery. The company has built a database of over 1 million molecules from plants, microbes, and marine organisms, analyzed via mass spectrometry and machine learning. Enveda targets inflammation, oncology, and metabolic diseases, partnering with pharmaceutical companies like Bristol Myers Squibb for lead optimization.

Immunai is a biotechnology company with locations in New York City, San Francisco, and Tel Aviv, mapping the immune system using single-cell genomics and machine learning. The firm profiles hundreds of immune cell types from blood samples via its proprietary database, aiding biomarker discovery for therapeutics in autoimmune diseases and cancer.

Mammoth Biosciences is a biotechnology company, co-founded by CRISPR pioneer Jennifer Doudna, that develops CRISPR-based tools for diagnostics and gene-editing therapeutics. Its platform is built around compact Cas proteins such as Cas14 and Casφ, which the company applies to in vivo gene editing for genetic and infectious diseases as well as decentralized disease detection. Mammoth has partnered with organizations including Regeneron, GSK, and the NIH, and has received government funding to develop COVID-19 testing technology.

Visby Medical is a diagnostics firm headquartered in Santa Barbara, California, specializing in rapid polymerase chain reaction tests for infectious diseases. Its instrument-free, single-use devices deliver PCR results in under 30 minutes. The company markets FDA-cleared tests for chlamydia, gonorrhea, and trichomoniasis in point-of-care and at-home formats, alongside multiplex assays for COVID-19, influenza A, and influenza B in clinical settings. Visby Medical's platform supports decentralized testing to accelerate disease detection.

Element Biosciences is a San Diego-based life sciences company building next-generation DNA sequencing instruments. The AVITI platform delivers high-accuracy reads using avidity sequencing chemistry, reducing costs through improved signal-to-noise ratios in surface chemistry and biochemistry. Launched in 2022, it supports workflows from short-read to long-read applications for genomics research. Element Biosciences serves academic labs, biopharma, and clinical sequencing markets worldwide.

Formation Bio is a South San Francisco-based biotechnology firm accelerating drug development through optimized clinical trials. It partners with pharma companies like Eli Lilly to redesign trial operations, leveraging technology for faster patient recruitment and data management in oncology and rare diseases.

MedGenome is a Bangalore-based genomics company offering next-generation sequencing diagnostics and research services for cancer, metabolic, cardiac, and rare diseases. The firm operates CLIA-certified labs in the United States and India, processing samples for over 500 hospitals and research institutions. Its platform integrates bioinformatics with population-scale data from South Asian genomes, supporting drug discovery partnerships with AstraZeneca and Bristol Myers Squibb in precision medicine initiatives.

Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. It also provides DecisionDx-UM, a risk stratification GEP test. The company also offers its products to the skin cancer and gastroenterology markets.